Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Capricor Therapeutics, Inc. logo — Capricor (NASDAQ: CAPR) is a biotechnology company developin...

Capricor Therapeutics, Inc.

Capricor (NASDAQ: CAPR) is a biotechnology company developing cell and exosome-based therapeutics for serious diseases.

Founded 2005 United States San Diego, United States 137 employees

General Information

Company Name Capricor Therapeutics, Inc.
Founded Year 2005
Location United States San Diego, United States +1
Employees 137
Social

Get notified when Capricor Therapeutics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Capricor Therapeutics, Inc.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

No funding data available for Capricor Therapeutics, Inc. yet.

Get notified when Capricor Therapeutics, Inc. raises funding

Capricor Therapeutics, Inc. Alternatives & Competitors

Capricor Therapeutics, Inc. vs
Muscular Dystrophy Association
Muscular Dystrophy Association United States

Faster breakthroughs, Stronger futures.

Grant
1179 employees
Health Care, Sports
Capricor Therapeutics, Inc. vs
Genea Biocells US, Inc.
Genea Biocells US, Inc. United States

Strength In Discovery

2 employees
Biotechnology, Health Care
Capricor Therapeutics, Inc. vs
BreStem Therapeutics, Inc.
BreStem Therapeutics, Inc. United States

BreStem is a clinical stage biotech company working to fight deadly lung diseases through stem cell...

1 employees
Biotechnology, Health Care

FAQ About Capricor Therapeutics, Inc.

Capricor (NASDAQ: CAPR) is a biotechnology company developing cell and exosome-based therapeutics for serious diseases.
Capricor Therapeutics, Inc. was founded in 2005.
Capricor Therapeutics, Inc. is headquartered in San Diego, United States.
Capricor Therapeutics, Inc. has approximately 137 employees.
Top alternatives and competitors to Capricor Therapeutics, Inc. include Muscular Dystrophy Association, Genea Biocells US, Inc., BreStem Therapeutics, Inc., Dyne Therapeutics, Elixirgen Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Capricor Therapeutics, Inc. and Muscular Dystrophy Association are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Capricor Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes